Rational approaches to resistance: Nucleoside analogues

AIDS, Supplement

Volumn 10, Issue 1, 1996, Pages

  Mayers, Douglas ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NONE   (United States)

Author keywords

Cross resistance; HIV protease inhibitors; Nucleoside HIV reverse transcriptase inhibitors; Resistance; Zidovudine

Indexed keywords

DIDANOSINE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PRIORITY JOURNAL; RISK; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0029826606     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Roberts NA: Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 1995, 9 (suppl 2):S27-S32.
2. Molla A, Kempf D, Korneyeva M, et al.: Characterization of the In vivo resistance pathway and pharmacokinetic properties of ritonavir. 5 International Workshop of HIV Drug Resistance. Whistler, July 1996 [abstract 31].
3. Jacobsen H, Haenggi M, Ott M, et al.: Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 1996, 29:95-97.
4. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989, 243:1731-1734.
5. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (ZDV). Science 1989, 246:1155-1158.
6. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
7. Boucher CAB, O'Sullivan E, Mulder JW, et al.: Ordered appearance of zidovudine-resistant mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992, 165:105-110.
8. Tudor-Williams G, St Clair MH, McKinney RE, et al.: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339:15-19.
9. Kozal MJ, Shafer RS, Winters MA, et al.: A mutation in HIV reverse transcriptase and decline in CD4+ lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993, 167:526-532.
10. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
11. Erice A, Mayers DL, Strike DG, et al.: Brief report: primary infection caused by zidovudine-resistant human immunodeficiency virus type 1 (HIV-1). N Engl J Med 1993, 328:1163-1165.
12. Fang G, Burger H, Grimson R, et al.: Maternal plasma HIV-1 RNA level: a determinant and threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92:12100-12104.
13. Anonymous: HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy. Lancet 1993, 341:1077-1078.
14. St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to didanosine and sensitivity to zidovudine induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
15. Shafer RW, Kozal MJ, Winters MA, et al.: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994, 169:722-729.
16. Gu Z, Gao Q, Fang H, et al.: Identification of a mutation at codon 65 in the IKKC motif of reverse transcriptase that encodes HIV resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994, 38:275-281.
17. Fitzgibbon JE, Howell RM, Haberzetti CA, et al.: Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992, 36:153-157.
18. Zhang D, Caliendo AM, Eron JJ, et al.: Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the HIV-1 reverse transcriptase. Antimicrob Agents Chemother 1994, 38:282-287.
19. Lin PF, Samanta H, Rose RE, et al.: Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on stavudine therapy. J Infect Dis 1994, 170:1157-1164.
20. Lacey SF, Larder BA: A novel mutation (V75T) in the HIV-1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in cell culture. Antimicrob Agents Chemother 1994, 38:1428-1432.
21. Gao Q, Gu ZX, Parniak MA, et al.: The same mutation that encodes low-level human immunodeficiency virus type-1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-)enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993, 37:1390-1392.
22. Schinazi RF, Lloyd RJ, Nguyen M-H, et al.: Characterization of human immunodeficiency viruses resistant to oxathiolanecytosine nucleosides. Antimicrob Agents Chemother 1993, 37:875-881.
23. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriplase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
24. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J Infect Dis 1994, 171:1411-1419.
25. Mayers DL, Japour AJ, Arduino JM, et al.: Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 1994, 38:307-314.
26. Lander BA: 3-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
27. Mellors JW, Bazmi HZ, Schinazi RF, et al.: Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 1995, 39:1087-1092.
28. Schooley RT, Ramtrez-Ronda C, Lange JMA, et al.: Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine montherapy. J Infect Dis 1996, 173:1354-1366.
29. Larder BA, Kemp SD, Harrigan R: Potential mechanism for sustained antiretroviral efficacy of AZT/lamivudine combination therapy. Science 1995, 269:696-699.
30. Shirasaka T, Kavlick MF, Ueno T, et al.: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
31. Emini EA, Condra JH, Schleif WA: Maintenance of long-term virus supression in patients treated with HIV-1 protease inhibitor Crixivan® (Indinavir). XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.170].
32. Connor EM, Sperling RS, Gelber R, et al.: Reduction of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.